1. Trang chủ
  2. » Kỹ Thuật - Công Nghệ

Pharmaceutical Substances Syntheses, Patents, Applications - Part 157 potx

10 147 0
Tài liệu đã được kiểm tra trùng lặp

Đang tải... (xem toàn văn)

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 10
Dung lượng 220,54 KB

Các công cụ chuyển đổi và chỉnh sửa cho tài liệu này

Nội dung

2 mg, 6 mg as acetate Trade Names: D: Monocortin Griinenthal; GB: Haldrate Lilly; wfm Paramezone Recordati F: Dilar Cassenne; wfm comb... Paroxetine P 1565 From fermentation solutions o

Trang 1

Paramethasone P 1561

1 chrornium(\rl)

oxide

21 -0cetoxy-6p-fluoro-17-hydroxy- 6a-fluoro-17.21 -dihydroxy-

16o-methylpregn-4-ene-3.20-dione 16a-methylpregn-4-ene-

3.20-dione (M)

1 microbiological

hydroxylation

2 111

w1 -+

disodium phosphate:

SeOz

Xs

dioxide

1 Paromethosone acetate

Reference(s):

US 2 671 752 (Syntex; 1954; appl 1951)

Djerassi, C et al.: J Am Chem Soc (JACSAT) 82, 2318 (1960)

- '? r - 7

1 O d - \ - L O ,

o

pyridine

2 acidic ion exchanger,

"'CH3 p

0 ' = phosphinic chloride

F

paramethasone

starling material:

Marker, R.E.; Crooks, H.M.: J Am Chem Soc (JACSAT) 64, 1280 (1942)

NaO

F

Paramethosone 21-disodium phosphate

alternative syntheses:

US 3 557 158 (Upjohn; 19.1.1971; appl 22.1.1962; prior 4.8.1958)

Schneider, P et al.: J Am Chem Soc (JACSAT) 81,3167 (1959)

GB 850 263 (Organon; appl 30.4.1959; NL-prior 12.5.1958)

US 4 041 055 (Upjohn; 9.8.1977; appl 17.1 1.1975)

disodiwn phosphate:

DE 1 134 075 (Merck AG; appl 26.1 1.1959)

Fom~dation(s): amp 20 mglml (as acetate); tabl 2 mg, 6 mg (as acetate)

Trade Name(s):

D: Monocortin (Griinenthal); GB: Haldrate (Lilly); wfm Paramezone (Recordati)

F: Dilar (Cassenne); wfm comb

Trang 2

1562 P Parethoxycaine

Para~nesone (Syntex- USA: Haldrone (Lilly); wfm Stero-Darvon (Li1ly)-

Use: local anesthetic RN: 94-23-5 MF: C,,H,,NO, MW: 265.35

CN: 4-ethoxybenzoic acid 2-(diethy1amino)ethyl ester

hydrochloride

RN: 136-46-9 MF: C,,H,NO, HCI MW: 301.81 EINECS: 205-246-4

reference!^):

US 2 404 691 (Squibb; 1946; prior 1937, 1944)

Formulation(s): tabl 0.75 mg (as hydrochloridc)

Trade Nan~e(s):

F: Maxicaine (Synthtlabo)

O J H 3

Porethoxycaine

Use: MAO-inhibitor, antihypertensive RN: 555-57-7 MF: CllH,3N MW: 159.23 EINECS: 209-101-6

LD,,: 56 mgkg (M, i.v.); 680 mglkg (M, p.0.);

300 mg/kg (R, p.o.)

CN: N-methyl-N-2-propynylbenzenemethanamine

hydrochloride

RN: 306-07-0 MF: C,,H,,N HC1 MW: 195.69 EINECS: 206-175-1

LD,,: YY m g k g (M, i.v.); 680 mgkg (M, p.0.):

175 mglkg (R, i.v.); 250 mglkg (R, p.0.);

175 mglkg (dog, p.0.)

N-benzylmethyl- p r o ~ a r g y l

Reference(s):

US 3 155 584 (Abbott; 3.11.1964; prior 3.12.1962)

Trang 3

Paricalcitol P 1563

Formulation(s): tabl 10 mg, 25 mg (as hydrochloride)

Trade Name(s):

Paricalcitol

(Paracalcin)

Use: vitamin D-analog, treatment for hyperparathyroidism

RN: 131918-61-1 MF: C,,H,O, MW: 416.65

25-hydroxyvitamin D2

(isolation from pig blood)

oso,,

pyridrne

+

osmium

tetroxide

1 Tos-CI

2 H3C-OH

3 H ~ c ~ o ~ ~ H , pyridine

b

la:25-dihydroxy-3,5-cydo-

vitamin D2 1-acetate

&methyl ether (1)

No104

,

sodium metaperiodate

111

+

Trang 4

1564 P Paromomycin

KOH CH30H _,

EP 387 077 (Wisconsin Alumni Res Found.; 12.9.1990; appl 9.3.1990; USA-prior 16.2.1990)

WO 9 729 740 (Wisconsin Alumni Res Found.; appl 5.9.1996; USA-prior 13.2.1996)

Paaren, H.E et al.: J Org Chem (JOCEAH) 45,3253-3258 (1980)

Paaren, H.E et al.: J Org Chem (JOCEAH) 48, 3819-3820 (1983)

treatment of osteoporosis in comb with growth hormone secretagogue:

WO 9 853 827 (Ramoz Univ.; appl 22.5.1998; IL-prior 30.5.1997)

Formulation(s): amp 5 pg/ml; 1 ml, 2 ml, 5 ml

Trade Name(s):

USA: Zemplar (Abbott; 1998)

Paromomycin

(Aminosidine)

ATC: A07AA06 Use: antibiotic RN: 7542-37-2 MF: C23H4SN50L4 MW: 61 5.63 EINECS: 23 1-423-0

LD,,,: 2.275 glkg (M, p.0.);

21.62 g/kg (R, p.0.)

P-D-ribofuranosyl-(1+5)]-2-deoxy-D-streptamine

sulfate

RN: 1263-89-4 MF: C,,H4,N,0,4~ xH,S04 MW: unspecified EINECS: 215-031-7

LD,,,: 90 m g k g (M, i.v.); 23.5 glkg (M, p.0.);

181 rng/kg (R, i.v.); 21.62 g/kg (R, p.0.)

Trang 5

Paroxetine P 1565

From fermentation solutions of Streptomyces rimosus forma paromomycinus or Streptomyces krestomyceticus

N.C.I.B 8995

Reference(s):

U S 2 916 485 (Parke Davis; 8.12.1959; prior 12.1.1959)

GB 880 035 (Soc Farmaceutici Italia; appl 31.3.1959; valid from 18.2.1960)

Formulation(s): cps 250 mg; powder 1 g; syrup 125 mg15 ml

Trude Name(s):

D: Humatin (Parke Davis) GB: Humatin (Parke Davis); Paramicina (Ragiomeri)

Humatin (Parkc Davis); Gabbroral (Carlo Erba) Sankyo)

Humatin (Parke Davis) wtm

Paroxetine

(BRL 29060; FG 705 1)

ATC: N06ABOS; N06AE Use: antidepressant, selective 5-HT-uptake inhibitor

RN: 61869-08-7 MF: C,,H,,FN03 MW: 329.37

LD,,: 374 mglkg (R, p.0.)

hydrochloride

RN: 78246-49-8 MF: C,9H2,FN03 HCI MW: 365.83

LD,,: 42 m g k g (M, i.v.); 3 7 8 m g k g ( M , p.0.);

30 m g k g (R, i.v.); 415 m d k g (R, p.0.)

hydrochloride hydrate (2:l)

RN: 110429-35-1 MF: C,,HzoFNO, HCl 112H20 MW: 749.68

maleate

RN: 64006-44-6 MF: ClyH,,FN03 xC4H,0, MW: unspecified

LD,,: 500 mglkg (M, p.0.); 845 mglkg (M s.c.)

acetate

RN: 72471-80-8 MF: Cl9HzOFNO3, C2H40z MW: 389.42

Trang 6

1566 P Paroxetine

arecoline

methylnipecotayl

chloride (11)

y"' 1 NaOCH,

2 SOCI,

F

4-fluorophenyl- rnognesium bromide (I)

F

methyl &/trans-4- (4-fluoropheny1)-N- methylnipecotate

OH

H,cd,,,'b distillotion

CH3 7 H 3

2 HBr

3 UAIH4 ,

1 (-)-menthol

3 lithium aluminum hydride

CI

S, decolin A

/ cuprous

methyl 1,4-dihydra-1-ethoxy- 4-(4-fluoropheny1)-

nlcotinate carbanyl-4-(4-fluora- 3-methoxycarbonyl-

phenyl]-3-methoxy- pyridine (N)

carbonylpyridine

7 H 3 I NOOCH,

N 2 LiAlH,

3 racemate resolution with H2 Pt o " " f ~ 0 ~ C H 3 (-)-di-p-toluoyltartaric acid ,

F methyl

bromide

Trang 7

Paroxetine P 1567

6;" +

F

4-fluora-

benz-

aldehyde

1 LiAlH,

2 rocernate resolution with (-)-di-p-toluoyl-

H

H3C 0 O

ethyl N-methyl-

malanomate

2 KOH

2 sodium 3.4-

pheny1)-3-((1.3-benzo- dioxol-5-yloxy)methyI]-1- rnethylpiparidine

ethyl p-fluorocinnomote ethyl cyono-

ocetote

Trang 8

1568 P Paroxetine

J-pyridine-

carbaraldehyde

Reference(s):

US 3 912 743 (Ferrosan, 14.10.1975; GB-prior 30.1.1973)

a,d US 4 007 196 (AIS Ferrosan; 8.2.1977; appl 23.7.1975; prior 21.1.1974; GB-prior 30.1.1973)

DE 2 404 1 13 (AIS Ferrosan; appl 29.1.1974; GB-prior 30.1.1973)

GB 1 422 263 (AIS Ferrosan; appl 30.1.1973)

b EP 219 934 (Beecham; appl 6.8.1986; GB-prior 10.8.1985)

c EP 223 334 (Beecham; appl 6.8.1986; GB-prior 10.8.1985, 23.5.1986)

e WO 9 853 824 (SmithKline Beecham; appl 29.5.1998; GB-prior 29.5.1997)

f WO 9 852 920 (Knoll; appl 1351998; GB-prior 17.5.1997)

g WO 9 724 323 (Chiroscience; appl 30.12.1996; GB-prior 29.12.1995)

alternative synthesis of 111:

EP 300 617 (Beecham; appl 17.6.1988; GB-prior 23.6.1987)

synthesis of arecoline:

The Merck Index, 1 lth Ed., 803 (Rahway 1989)

optically pure precursors:

US 52 582 5 17 (Sepracor; 2.11.1993; appl 6.8.1992)

ctys!alline hydrochloride hemihydrate:

EP 223 403 (Beecham; appl 14.10.1986; GB-prior 25.10.1985)

US 4 721 723 (Beecham; 26.1.1988; appl 23.10.1986; GB-prior 25.10.1985)

medical use for treatment of pain:

EP 269 303 (Beecham; appl 9.1 1.1986; GB-prior 11.1 1.1985)

medical use for treatment of obesity:

EP 188 08 1 (Ferrosan; appl 2.12.1985; GB-prior 4.12.1984)

preparation of easily soluble paroxetine:

WO 9 831 365 (SmithKline Beecham; appl 12.1.1998; GB-prior 15.1 l997)

new polymorph of anhydrous paroxetine:

CA 2 187 128 (Brabtfort Chem.; appl 4.10.1996)

method of producing amorphous paroxetine:

EP 810 224 (Asahi Glass; appl 30.5.1997; J-prior 30.5.1996)

US 5 672 612 (Pentech Pharm; USA-prior 9.9.1996)

controlled-release pharmaceutical compositions:

WO 9 703 670 (SmithKline Beecham; appl 19.7.1996; GB-prior 20.7.1995)

Formulation(s): tabl., 20 mg, 30 mg (as hydrochloride)

Trade Name(s):

D: Seroxat (SmithKline F: Dexorat (SmithKline GB: Seroxat (SmithKline

Tagonis (Janssen-Cilag)

Trang 9

Parsalmide f' 1569

1: Sereupin (Ravizza) Seroxat (SmithKline USA: Paxil (SmilhKline

Use: anti-inflammatory RN: 30653-83-9 MF: Cl,H1,N202 MW: 246.3 1 EINECS: 250-274-2

LDS,,: 148 mglkg (M, i.v.); 428 mgtkg (M, p.o.);

864 mg/kg (R, p.0.)

CN: 5-amino-N-butyl-2-(2-propyny1oxy)benzamide

2 NoOH

chloride

5-ocetamido-0-ocetyl- 5-ocetomido-0-ocetyl-

5-acetomido-N-butyl- proparw

Porsolmide

Reference(s):

DOS 2 029 991 (E.R.A.S.M.E.; appl 18.6.1970; GB-prior 20.6.1969)

US 3 739 030(E.R.A.S.M.E.; 12.6.1973; GB-prior 20.6.1969)

Pedrazzoli, A et al.: Chim Ther (CHTPBA) 3, 200 (1968)

ulternative synthesis:

GB 1 539 007 (C M Ind.; valid from 26.10.1977; F-prior 8.11.1976)

Fortnulution(s): drg 200 mg, 400 mg; f c tabl 600 mg; s r tabl 800 mg

Trade Name(s):

1: Parsal (Midy); wfm

Use: tuberculostatic antibacterial RN: 2066-89-9 MF: C7H,N0, C,H,N,O MW: 290.28 EINECS: 218-183-2

CN: 4-pyridinecarboxylic acid hydrazide mono(4-amino-2-hydroxybenzoate)

Trang 10

1570 P Pecazine

$ +

CII OH 60 "C

_F ,

,NH2

0 N NH2

(9 v.)

Reference(s):

CH 303 085 (Roche; appl 1952)

Fonnulation(s): tabl 100 mg

Trade Name(s):

1): Dipasic (Gewo); wfm Pasiniazide Rolland

F: Paraniazide (L'HCpatrol); (L'HCpatrol); wfm

Pecazine

(Mepazine)

ATC: N05A IJse: neuroleptic

RN: 60-89-9 MF: C,,H,N,S MW: 310.47 EINECS: 200-490-8

LD,,: 70 m g k g (M, i.v.)

monoacetate

RN: 24360-97-2 MF: Cl9HZ2N2S C2H40, MW: 370.52 EINECS: 246-207-1

monohydrochloride

RN: 2975-36-2 MF: C19H2zN2S HCl MW: 346.93 EINECS: 221-020-8 LD,,,: 62mg/kg(M,i.v.); 155mg/kg(M,p.o.);

20 m g k g (R, i.v.); 1 glkg (R, p.0.)

FH3

sodium

Reference(s):

US 2 784 185 (Promonta; 1957; D-prior 1953)

Forrnulafion(s): tabl 50 rng, 400 mg (as hydrochloride)

Trade Name(s):

D: Pacatal (Promonta); wfrn

Ngày đăng: 02/07/2014, 02:20

TỪ KHÓA LIÊN QUAN

🧩 Sản phẩm bạn có thể quan tâm